Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on June 2, 2025

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial …

TruGolf Announces Listing Extension from Nasdaq
Salt Lake City, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, today announced that the Nasdaq Hearings Panel has granted the company an extension of time to comply with Nasdaq listing …

NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking
BANGKOK, June 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced plans …

Robex Reports Operational and Financial Results for Q1 2025
QUÉBEC CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX/ASX: RXR) Matthew Wilcox, Managing Director, commented: "The company has had a strong start to 2025, construction continues to advance at Kiniero, and …

Robotics Lubricants Market Size Expected to Surpass $14.25 Billion by 2031, Expanding at 11.0% CAGR from 2023-2031 | The Insight Partners
US …

Fancamp Announces Appointment of CIO
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) is pleased to announce the appointment of Mr. Kit Spring to the position of Chief Investment Officer (“CIO …

Plexus Issues Fiscal 2024 Sustainability Report
NEENAH, Wis., June 02, 2025 (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) today released its fiscal 2024 Sustainability Report. The report, which is now available on the company’s Sustainability web page, highlights how Plexus’ commitment to …

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, …

Joint Press Release of Constellation Software Inc. and Topicus.com Inc. -- Topicus.com Inc. completes acquisition of Cipal Schaubroeck in Belgium
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus’ subsidiary Total Specific Solutions (TSS) B.V. (“TSS”) has completed the sale and transfer of all issued and …

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly …

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines …

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic biotechnology company, today announced the closing of a $ …

Fasoo Smart Screen Bolsters Supply Chain Security with Advanced Screen Protection
SEOUL, SOUTH KOREA, June 2, 2025 /EINPresswire.com/ -- Fasoo, the leader in data-centric security, introduces new momentum for Fasoo Smart Screen (FSS), its advanced screen security solution designed to control unauthorized screen capture tools and …

COS Systems expands Open Access Services partnership with Fujitsu
Extended partnership enables turn-key Open Access network operations backed by COS Business Engine. WEST PALM BEACH, FL, UNITED STATES, June 1, 2025 /EINPresswire.com/ -- COS Systems continues to strengthen its partnership with Fujitsu, a leading …

ASML reports transactions under its current share buyback program
ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average …

STMicroelectronics Announces Status of Common Share Repurchase Program
STMicroelectronics Announces Status of Common Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 26, 2025 to May 30, 2025 AMSTERDAM – June 2, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global …

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …

Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- What if everything we thought we knew about pain was wrong? Today, more than 1 in 5 Americans live with chronic pain, and too often, their pain is met with silence, surgery, or a prescription pad. Now, …

Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of …